연구분야 ( 코드 ) 과제번호 과제성격 ( 기초, 응용, 개발 ) 연구과제명 과제책임자 세부과제 실용화대상여부 실용화 / 비실용화 지원 ex) 창의 프로그램 ( 일반연구 ) 과제공개가능여부 ( 공개, 비공개 ) γ γ 구분 1 2 3 소속위암연구과직위선임연구원 성명조수정전공내과 세부과제명 세부과제책임자 성명 소속 ( 직위 ) 전공 총연구기간 2012 년 3 월 ~ 2013 년 12 월 ( 총 2 년 ) 참여연구원수 ( 단위 : 명, MY) 연구기간및 연구비 ( 단위 : 천원 ) 구분연구기간계 계 제 1 차 제 2 차 제 3 차 2012 년 3월~2013년 12월 2012년2월~2012 년12월 2013년1월~2013 년 12 월 ~ 국립암센터 100.000 100,000 50,000 50,000 50,000 50,000 참여기업명칭전화 FAX 기업부담금소계현금현물 기관고유연구사업관리규칙에따라본연구개발사업을성실히수행하였으며아래와같이최종보고서 를제출합니다. 2013 년 10 월 31 일 과제책임자조수정 ( 서명 )
작성요령
< 최종목표 > 연구목표 (200 자이내 ) 연구내용및방법 (500 자이내 ) < 당해연도목표 > 연구개발에따른기대성과 γ 국문 γ 색인어 영문 γ
γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ
γ
γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ γ κ γ κ κ
γ κ γ γ γ β γ γ γ γ γ γ
γ γ γ γ γ
γ
2. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87(2):236-42. 3. Marrelli D, Roviello F, De Stefano A, Fotia G, Giliberto C, Garosi L, et al. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection. J Am Coll Surg 2004;198(1):51-8.
4. Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol 2003;10(8):898-902. 5. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther;9(12):3221-32. 6. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49. 7. Makola D, Peura DA, Crowe SE. Helicobacterpyloriinfectionandrelatedgastrointestinaldiseases.JClinGastroenterol2007;41(6):548-58. 8. Cho SJ, Choi IJ, Kim CG, Lee JY, Kook MC, Seong MW, et al. HelicobacterpyloriSeropositivityIsAssociatedwithGastricCancerRegardlessofTumorSubtypeinKorea.GutLiver20 10;4(4):466-74. 9. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--first American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52(24):6735-40. 10. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289-312. 11. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A 2002;99(21):13771-6. 12. PPARgamma and apoptosis in cancer. PPAR Res 2008;2008:704165. 13. Wang YL, Miao Q. To Live or to Die: Prosurvival activity of PPARgamma in cancers. PPAR Res 2008;2008:209629. 14. Burton JD, Goldenberg DM, Blumenthal RD. Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008;2008:494161. 15. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4(9):1053-7. 16. Yang K, Fan KH, Lamprecht SA, Edelmann W, Kopelovich L, Kucherlapati R, et al. Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal
C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice. Int J Cancer 2005;116(4):495-9. 17. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000;83(10):1394-400. 18. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008;123(4):951-7. 19. Jin SW, Beis D, Mitchell T, Chen JN, Stainier DY. Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. Development 2005;132(23):5199-209. 20. Takeda H. [Maintenance of laboratory strain of zebrafish, Danio rerio]. Tanpakushitsu Kakusan Koso 1999;44(6):803-6. 21. Nicoli S, Presta M. The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc 2007;2(11):2918-23. 22. Kim SJ, Shin JY, Lee KD, Bae YK, Choi IJ, Park SH, et al. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 2011;6(9):e25103. 23. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011;14(2):113-23. 24. Sobin LH, Wittekind C. TNM classification of malignant tumors, 6th ed. Wiley-Liss: New York, 2002. 25. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998;1(1):10-24. 26. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358(6389):771-4. 27. He Q, Pang R, Song X, Chen J, Chen H, Chen B, et al. Rosiglitazone suppresses the growth and invasiveness of SGC-7901 gastric cancer cells and angiogenesis invitroviappargammadependentandindependentmechanisms.pparres2008;2008:649808. 28. Lu J, Imamura K, Nomura S, Mafune K, Nakajima A, Kadowaki T, et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res 2005;65(11):4769-74.
29. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, et al. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 2009;136(4):1242-50. 30. Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, Febbraro A, et al. Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 2009;40(5):714-25. 31. Gupta RA, Polk DB, Krishna U, Israel DA, Yan F, DuBois RN, et al. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacterpyloriingastricepithelialcells.JBiolChem2001;276(33):31059-66. 32. Yang GF, Deng CS, Xiong YY, Gong LL, Wang BC, Luo J. Expression of nuclear factor-kappa B and target genes in gastric precancerous lesions and adenocarcinoma: association with HelicobactorpyloricagA(+)infection.WorldJGastroenterol2004;10(4):491-6. 33. Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, et al. A functional single nucleotide polymorphism in mucin1,atchromosome1q22,determinessusceptibilitytodiffuse-typegastriccancer.gastroenterology2011;140(3): 892-902 34. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, et al. Dysregulation of cellular signaling in gastric cancer. Cancer Lett 2010;295(2):144-53. 35. Pancione M, Sabatino L, Fucci A, Carafa V, Nebbioso A, Forte N, et al. Epigenetic silencing of peroxisome proliferator-activated receptor gamma is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One 2010;5(12):e14229. 36. Takano S, Kubota T, Nishibori H, Hasegawa H, Ishii Y, Nitori N, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 2008;28(6A):3593-9. 37. Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ, et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110(7):923-32. 38. Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, et al. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer;106(9):1486-94. 39. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994;76(4):597-8.
40. Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, Takeshita K, et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 2008;18(9):735-44. 41. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005;11(8):2962-8. 42. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial-mesenchymal transition. Cancer Res 2008;68(23):9574-7. 43. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2(6):442-54. 44. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133(4):704-15. 45. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9(4):265-73.